Organogenesis VP disposes 18,619 shares for taxes

Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at $3.73 per share to cover tax obligations, leaving him with 178,061 directly owned shares.

Insider Trade Summary

Exercise Price or Tax Liability: 18,619 shares

Exercise Price or Tax Liability 4 txns

Insider Montecalvo Antonio S.

Role Vice President, Health Policy

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	1,389	$3.73	$5K
Exercise Price or Tax Liability	Class A Common Stock	9,607	$3.73	$36K
Exercise Price or Tax Liability	Class A Common Stock	4,100	$3.73	$15K
Exercise Price or Tax Liability	Class A Common Stock	3,523	$3.73	$13K

Holdings After Transaction: Class A Common Stock — 178,061 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Organogenesis (ORGO) report for Antonio S. Montecalvo?

Organogenesis vice president Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. These transactions used shares to satisfy tax obligations rather than representing open-market sales.

How many Organogenesis (ORGO) shares were disposed of in the tax-withholding transactions?

A total of 18,619 Organogenesis Class A Common Stock shares were disposed of through tax-withholding transactions. Individual lots were 1,389, 9,607, 4,100, and 3,523 shares, each recorded as payment of tax liability by delivering securities.

At what price were the Organogenesis (ORGO) tax-withholding shares valued?

The tax-withholding dispositions were valued at a transaction price of $3.73 per share. This price applied to each of the four Class A Common Stock transactions executed on February 15, 2026, for Antonio S. Montecalvo.

How many Organogenesis (ORGO) shares does Antonio S. Montecalvo own after the transactions?

After the reported tax-withholding dispositions, Antonio S. Montecalvo directly owns 178,061 shares of Organogenesis Class A Common Stock. This post-transaction balance reflects the final line item reported for his direct ownership in the filing.

What does transaction code "F" mean in the Organogenesis (ORGO) Form 4?

Transaction code “F” on the Form 4 indicates payment of an exercise price or tax liability by delivering securities. For Organogenesis, Antonio S. Montecalvo used shares of Class A Common Stock to cover tax obligations, rather than executing a typical market sale.

Are the Organogenesis (ORGO) insider transactions classified as direct or indirect ownership changes?

All reported Organogenesis transactions for Antonio S. Montecalvo are classified as direct ownership changes. The Form 4 lists ownership type and code as direct (“D”) for each tax-withholding disposition of Class A Common Stock on February 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montecalvo Antonio S.

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Health Policy

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/15/2026		F		1,389	D	$3.73	195,291	D
Class A Common Stock	02/15/2026		F		9,607	D	$3.73	185,684	D
Class A Common Stock	02/15/2026		F		4,100	D	$3.73	181,584	D
Class A Common Stock	02/15/2026		F		3,523	D	$3.73	178,061	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stacie S. Aarestad, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.